<DOC>
	<DOCNO>NCT02213107</DOCNO>
	<brief_summary>Determine effect enzalutamide dutasteride time prostatic-specific antigen level increase patient age 65 older .</brief_summary>
	<brief_title>Enzalutamide &amp; Dutasteride 1st Line Treatment Patients =/ &gt; 65 Years Old With Prostate Cancer .</brief_title>
	<detailed_description>The primary objective study determine effect enzalutamide dutasteride time prostatic-specific antigen progression patient age 65 old receive combination first line treatment systemic prostate cancer . To determine safety toxicity study drug combination . To determine time prostatic-specific antigen nadir start study treatment evaluate absolute prostatic-specific antigen nadir result study drug combination</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate without neuroendocrine differentiation small cell feature . Patients systemic prostate cancer define either ) hormonal naïve metastatic prostate cancer radiographic evidence visceral osseous metastasis b ) biochemical recurrence prostate cancer fulfill follow criterion : A minimum three rise prostaticspecific antigen level interval =/ &gt; 1 week test , The prostaticspecific antigen ( PSA ) value screen visit =/ &gt; 2 ng/ml prostaticspecific antigen double time ≤ 9 month . Patients 65 year old . Patients deem `` fit '' comprehensive geriatric assessment high risk side effect determine treat physician . A case report form use document specific eligible patient consider ideal candidate . Serum testosterone level &gt; 1.7 nmol/L ( 50 ng/dL ) screen visit ( non castrate ) . Patients could receive hormonal therapy part definitive treatment previous localized prostate cancer . However , hormonal therapy great six month prior entry clinical trial . Eastern Cooperative Oncology Group performance status 0 2 . Able swallow study drug comply study requirement . Severe concurrent disease infection , judgment investigator , would make patient inappropriate enrollment . Known brain metastasis . Brain imaging study require eligibility patient neurologic sign symptom suggestive brain metastasis . However , brain imaging study perform , must negative disease . Patient receive treatment another active malignancy exclude localize cutaneous squamous basal cell carcinoma . Prior treatment systemic prostate cancer . Prior treatment enzalutamide . Treatment androgen receptor antagonist ( bicalutamide , flutamide , nilutamide , ) , ketoconazole , abiraterone , finasteride , dutasteride , estrogens , chemotherapy adjuvant set within 6 month enrollment ( Day 1 visit ) plan initiate treatment treatment . Treatment therapeutic immunization prostate cancer ( e.g. , PROVENGE® ) plan initiate treatment treatment study period . Use herbal product may decrease prostaticspecific antigen level ( e.g. , saw palmetto ) systemic corticosteroid great equivalent 10 mg prednisone/prednisolone per day within 4 week enrollment ( Day 1 visit ) plan initiate treatment treatment study . Radiation therapy within 3 week ( single fraction radiotherapy within 2 week ) radioisotope therapy within 8 week enrollment ( Day 1 visit ) . Participation previous clinical trial investigational agent block androgen synthesis within six month . Participation previous clinical trial enzalutamide . Use investigational agent within 4 week enrollment ( Day 1 visit ) plan initiate treatment investigational agent study . Have use plan use 30 day prior enrollment ( Day 1 visit ) end study follow medication know low seizure threshold increase decrease bioavailability drug . Concomitant use strong moderately strong Cytochrome P450 isozyme inducer : Strong Cytochrome P450 isoenzyme 2C8 inhibitor like gemfibrozil , Strong Cytochrome P450 isoenzyme 2C8 inducer like Rifampin , Strong Cytochrome P450 isoenzyme 3A4 inhibitor like Itraconazole , Aminophylline/theophylline , Atypical antipsychotic ( e.g. , clozapine , olanzapine , risperidone , ziprasidone ) , Bupropion , Class IA Class III antiarrhythmic ( e.g. , amiodarone , bretylium , disopyramide , ibutilide , procainamide , quinidine , sotalol ) ; Dolasetron , Droperidol , Lithium , Macrolide antibiotic ( e.g. , erythromycin , clarithromycin ) ; Pethidine , Phenothiazine antipsychotic ( e.g. , chlorpromazine , mesoridazine , thioridazine ) ; Pimozide , Tricyclic tetracyclic antidepressant ( e.g. , amitriptyline , desipramine , doxepin , imipramine , maprotiline , mirtazapine ) . History seizure , include febrile seizure , loss consciousness , transient ischemia attack within 12 month enrollment ( Day 1 visit ) , condition may predispose seizure ( e.g. , prior stroke , brain arteriovenous malformation , head trauma loss consciousness require hospitalization ) . Clinically significant cardiovascular disease include : Myocardial infarction within 6 month , Uncontrolled angina within 3 month , Congestive heart failure New York Heart Association class 3 4 , patient history congestive heart failure NYHA class 3 4 past , unless screen echocardiogram multigated acquisition scan perform within 3 month result leave ventricular ejection fraction =/ &gt; 45 % , hypotension ( systolic blood pressure &lt; 86 millimeter mercury [ mmHg ] bradycardia heart rate &lt; 50 beat per minute , uncontrolled hypertension indicate rest systolic blood pressure 170 mmHg diastolic blood pressure &gt; 105 mmHg Screening Study Day 1 visit . Gastrointestinal disorder affect absorption ( e.g. , gastrectomy , active peptic ulcer within last 3 month ) . Major surgery within 4 week prior enrollment ( Day 1 visit ) . Absolute neutrophil count &lt; 1,500/µL , platelet count &lt; 100,000/µL , hemoglobin &lt; 5.6 mmol/L ( 9 g/dL ) Screening visit ; ( NOTE : patient may receive growth factor blood transfusion within 7 day hematologic laboratory value obtain Screening visit ) .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>prostate</keyword>
</DOC>